Tag: NET cancer

Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment

Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA).  LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…

Twitter Chat on Rare Disease Day to Focus on Carcinoid and NET Cancers

Join us on Rare Disease Day, February 29th, for a Twitter chat about NET (neuroendocrine tumor) cancers with Steven K. Libutti, MD, Director of Montefiore Einstein Center for Cancer Carein New York. The chat will begin at 2 pm, Eastern Time.

Follow @MontefioreNews…

Carcinoid and Pancreatic Neuroendocrine Tumor Cancer Survivors Share Their Journeys

The Carcinoid Cancer Foundation is pleased to announce the addition of several new Survivor Stories on its website, www.carcinoid.org.  These are stories of courageous carcinoid and pancreatic neuroendocrine tumor (NET) survivors who, in several…

Worldwide NET Cancer Awareness Day Update: Events from Australia to Europe to North America

Go around the globe for the second Worldwide NET Cancer Awareness Day (WNCAD) on November 10, 2011. Throughout that day, videos featuring NET events and experts will air on www.netcancerday.org  as the sun travels west, from Australia to Europe to North…

Breaking News: Pancreatic NET Cancer Patient Steve Jobs Steps Down as CEO of Apple

On August 24, 2011, Steve Jobs, CEO of Apple, announced that he was stepping down from his position.  In his letter to the Apple Board of Directors and the Apple Community, Mr. Jobs wrote, “I have always said if there ever came a day when I could no longer meet…

Worldwide NET Cancer Awareness Day Updates

With less than five months until the second Worldwide NET Cancer Awareness Day on Thursday, November 10, 2011, there have been many exciting developments to share with the carcinoid and NET community.

The first Chinese NET website (www.net.org.tw) …

1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)

Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …

Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting

Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim…

Carcinoid Cancer Foundation Symposium Features Leading NET Cancer Specialists & a Patient Panel

What are the most state-of-the-art treatments for carcinoid and NET cancer patients today?  Join us on May 1st when the Carcinoid Cancer Foundation presents its 14th Annual Symposium, “Neuroendocrine Tumor Management: The Era of Personalized…